The China market for early-screening cancer products has grown rapidly in recent years, fueled by the country’s huge cancer caseload and a growing middle class that can afford such services. One major beneficiary of that boom is New Horizon Health Ltd. (6606.HK), whose latest results released last week show its revenue more than tripled to 765 million yuan ($110.8 million) last year.
作者莫莉，本文僅代表個人觀點。
您已閱讀5%（401字），剩余95%（7715字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。